| Methods |
Randomised using permutation blocks. Double blind, parallel, placebo controlled trial |
| Participants |
Country: Germany, multicentre, Selection criteria: mild‐moderate Alzheimers disease, HIS <4, MMSE 13‐23, NINCDS‐ADRDA criteria. |
| Interventions |
1. ALC 3g/day for 1 year
2. Placebo for 1 year |
| Outcomes |
MMSE, BIMC, CGI‐C, CGI‐E, CGI‐S, NAS, BDS, RGDS |
| Notes |
Data from Sigma‐Tau, unpublished. Unusual results‐ improvement over one year. Not usual clinical course for dementia. Raises issue of incorrect diagnosis. |
